Last year, scientists at the Albert Einstein College of Medicine, the United States Army Medical Research Institute for Infectious Diseases and Harvard Medical School cited bio-specimens from the
NIGMS Repository.
When an individual donates a sample to the
NIGMS Repository, they are providing scientists all over the world with the very valuable opportunity to learn more about their specific disease and how their specific genetic make-up influences the symptoms and behaviors associated with their diagnosis.
More information on
NIGMS human embryonic stem cell initiatives can be found at www.
Eighteen of the cell lines were derived from residual blood samples as described, and 6 were selected from the
NIGMS Human Genetic Cell Repository.
For more information on
NIGMS initiatives related to human embryonic stem cells, go to: www.
NIGMS is part of the National Institutes of Health.
Currently,
NIGMS research training programs are only open to holders of MD and PhD degrees (35).
Supported in part by
NIGMS R25 GM50117 and REAP, NAS.
We screened 13 cell lines from the
NIGMS Repository for medically important mutations in 11 different genes: CFTR, F5, F2, MTHFR, HFE, GJB2 (connexin 26), FMR1 (fragile X), HBA1/HBA2 ([alpha]-thalassemia), FGFR3, HD, and HbS/HbC.
NIGMS will supply $150 million over five years to seven research groups based throughout the US.
This study was supported by a grant from the
NIGMS (to DS).
This Request for Information (RFI) will assist
NIGMS in considering the biomedical technology research and development space at all stages, from exploratory to mature.
